Documentary – Top Secret Kapustin Yar – Russia’s Area 51
This show looks into that activities of Kapustin Yar — a remote, top secret, military development and test facility in Russia and said to be the former Soviet Union’s version of Area 51. Kapustin Yar (Russian: Капустин Яр) is a Russian rocket launch and development site in Astrakhan Oblast, between Volgograd and Astrakhan. Known today as Znamensk (Russian: Знаменск), it was established 13 May 1946 and in the beginning used technology, material and scientific support from defeated Germany. Numerous launches of test rockets for the Russian military were carried out at the site, as well as satellite and sounding rocket launches. Open Street Map of the area. The 4th Missile Test Range “Kapustin Yar” was established by a decree of the Soviet Government “On Questions of Jet Propelled Weapons” on 13 May 1946. The test range was created under the supervision of General-lieutenant Vasily Voznyuk (commander in chief of the test range 1946-1973) in the desert north end of the Astrakhan region. The first rocket was launched from the site on 18 October 1947; it was one of eleven German A-4s that had been captured. The State R&D Test Range No 8 (GNIIP-8, “test range S”) was established at Kapustin Yar in June 1951. Five atmospheric nuclear tests of small power (10-40 kt) were performed over the site in 1957-1961. With the further growth and development, the site became a cosmodrome, serving in this function since 1966 (with interruption in 1988-1998). The town of Znamensk was established to support the scientists working on the facilities, their families and supporting personnel. Initially this was a secret city, not to be found on maps and inaccessible to outsiders. Evidence of the importance of Kapustin Yar was obtained by Western intelligence through debriefing of returning German scientists and spy flights. The first such flight reportedly took place in mid-1953 using a high flying Canberra aircraft of the RAF. Numerous circumstantial reports suggest this flight took place, using the Canberra PR3 WH726, but the UK Government has never admitted such a flight took place nor have any of the supposed participants provided direct evidence The Canberra took off from Giebelstadt Air Base, Germany, and, flying via the Volga to the Caspian Sea, landed at Tabriz, Iran. Due to its role as a development site for new technology, Kapustin Yar is also the site of numerous Soviet-era UFO sightings and has been called “Russia’s Roswell”.
US National Library of Medicine
National Institutes of Health – Jan 2009
Study – Do childhood vaccines cause thrombocytopenia?
Laura J Sauvé, MD MPH and David Scheifele, MD
Vaccine Evaluation Centre, BC Children’s Hospital, Vancouver, British Columbia
Correspondence: Dr Laura Sauvé, Vaccine Evaluation Centre, Shaughnessy Site, Room L427, 4500 Oak Street, Vancouver, British Columbia
An increasing body of evidence has been gathered since the mid-1960s to support a link between vaccinations, particularly the measles-mumps-rubella (MMR) vaccine and idiopathic thrombocytopenic purpura (ITP). The incidence rate is estimated to be between one in 25,000 to one in 40,000 doses of MMR (1,2); this is much less frequent than after natural infection with measles (common), rubella (one in 3000 cases) and varicella. The purpose of the present commentary is to review vaccine-associated thrombocytopenia (VATP).
Vaccine-preventable diseases are becoming rare in Canada, with an average of 10 reported cases of measles per year between 2002 and 2006; although there was a large outbreak in Quebec in 2007, with 95 confirmed cases (3). With widespread vaccination and the near disappearance of vaccine-preventable diseases in Canada, there is less societal tolerance for adverse events following immunization (AEFI). One of the challenges in assessing AEFIs is distinguishing events that are causally linked with vaccination from those that are only temporally associated. Cases of thrombocytopenia in the first month after vaccination often have a history of recent viral infection or coadministration of medications that may also lead to thrombocytopenia, making the actual cause of VATP difficult to identify.
Since 1992, the Immunization Monitoring Program, ACTive (IMPACT), conducted by the Canadian Paediatric Society, has performed active surveillance for children who are hospitalized with AEFIs, including VATP. Trained nurse monitors at each of the 12 IMPACT centres review all admissions for children admitted for VATP (children with a platelet count of less than 100×109/L and no obvious other cause, such as cancer chemotherapy) within one month of documented receipt of any vaccine. Jadavji et al (4) reported on the first nine years of surveillance (with 61 cases) for VATP in 2003. One of the limitations in the IMPACT data is that detecting a case requires the treating physician to document administration of a vaccine in the previous month (the nurse monitors do not interview the parents). A recent American study (1) found that treating physicians had asked only two of 13 children with VATP about recent vaccination.
The IMPACT data on VATP are similar to reports from other countries, including the United Kingdom, France and the United States (1,2,5,6). In Canada, 103 cases of VATP have been documented by IMPACT since 1992 (7). The median age was 13 months, and 61% of those affected were boys. Petechial rash and bruising were the typical presenting signs. Most (73%) cases were treated with intravenous immunoglobulin. Most children did quite well, with rapid recovery; only six of 95 children with follow-up data still had abnormal platelet counts after three months. However, two children had severe bleeding-related complications, one had a gastrointestinal bleed requiring intensive care and one had post-traumatic intracranial bleeding leading to death.
Most cases of VATP are associated with MMR or measles vaccine, including 72% of the cases reported to IMPACT (25 of these 74 children had received one or more additional vaccines, including 10 children who also received the diphtheria, pertussis and tetanus vaccine, and 10 children who had received the varicella vaccine). Of the children who had MMR associated with thrombocytopenia in the IMPACT study, nine (12%) had a previous recorded dose of the vaccine without known thrombocytopenia. When all of the VATP cases were considered, 31% of the VATP episodes occurred after the second or third exposure to a vaccine.
US National Library of Medicine
National Institutes of Health – Sep 2011
The infant mortality rate (IMR) is one of the most important indicators of the socio-economic well-being and public health conditions of a country. The US childhood immunization schedule specifies 26 vaccine doses for infants aged less than 1 year—the most in the world—yet 33 nations have lower IMRs. Using linear regression, the immunization schedules of these 34 nations were examined and a correlation coefficient of r = 0.70 (p < 0.0001) was found between IMRs and the number of vaccine doses routinely given to infants. Nations were also grouped into five different vaccine dose ranges: 12–14, 15–17, 18–20, 21–23, and 24–26. The mean IMRs of all nations within each group were then calculated. Linear regression analysis of unweighted mean IMRs showed a high statistically significant correlation between increasing number of vaccine doses and increasing infant mortality rates, with r = 0.992 (p = 0.0009). Using the Tukey-Kramer test, statistically significant differences in mean IMRs were found between nations giving 12–14 vaccine doses and those giving 21–23, and 24–26 doses. A closer inspection of correlations between vaccine doses, biochemical or synergistic toxicity, and IMRs is essential.
A buried JAMA study from almost a decade ago which showed that there was no improvement in mortality rates among senior citizens with a flu vaccine, even after greatly increased vaccination rates. The study “got little attention,” she says, “because the science came down on the wrong side.” Whereas the researchers had set out to prove that the push for massive flu vaccination would save the world, the researchers were “astonished” to find that the data did not support their presupposition at all. The data actually shows that deaths increased, not decreased, among seniors following vaccination.
Johns Hopkins scientist, Peter Doshi, Ph.D., issued a report in the prestigious British Medical Journal, according to NewsLI, asserting that the CDC policy of routinely recommending the flu vaccine is being based on “low quality studies that do not substantiate claims.” He says there is no evidence that the vaccine reduces deaths among senior citizens. Interestingly, Doshi cites an Australian study which found significant risks for children as well, stating that “one in every 110 children under the age of five had convulsions following vaccinations in 2009 for H1N1 influenza.”
During the drug trials for the Fluzone flu vaccine, 23 seniors out of 3,833 died after receiving the shot, according to the drug’s package insert, reported by Health Impact News. Another 226 experienced “serious adverse effects.” The manufacturer denies any connection between the deaths and the flu vaccine.
Lone Simonsen, PhD; Thomas A. Reichert, MD, PhD; Cecile Viboud, PhD;
Abstract
Background Observational studies report that influenza vaccination reduces winter mortality risk from any cause by 50% among the elderly. Influenza vaccination coverage among elderly persons (≥65 years) in the United States increased from between 15% and 20% before 1980 to 65% in 2001. Unexpectedly, estimates of influenza-related mortality in this age group also increased during this period. We tried to reconcile these conflicting findings by adjusting excess mortality estimates for aging and increased circulation of influenza A(H3N2) viruses.
Methods We used a cyclical regression model to generate seasonal estimates of national influenza-related mortality (excess mortality) among the elderly in both pneumonia and influenza and all-cause deaths for the 33 seasons from 1968 to 2001. We stratified the data by 5-year age group and separated seasons dominated by A(H3N2) viruses from other seasons.
Results For people aged 65 to 74 years, excess mortality rates in A(H3N2)-dominated seasons fell between 1968 and the early 1980s but remained approximately constant thereafter. For persons 85 years or older, the mortality rate remained flat throughout. Excess mortality in A(H1N1) and B seasons did not change. All-cause excess mortality for persons 65 years or older never exceeded 10% of all winter deaths.
Conclusions We attribute the decline in influenza-related mortality among people aged 65 to 74 years in the decade after the 1968 pandemic to the acquisition of immunity to the emerging A(H3N2) virus. We could not correlate increasing vaccination coverage after 1980 with declining mortality rates in any age group. Because fewer than 10% of all winter deaths were attributable to influenza in any season, we conclude that observational studies substantially overestimate vaccination benefit.
VAXXED TV – Military vaccines made me sick
I Slept My Teenage Years AWAY! Kelly recalls life before and after given vaccines during a swine flu epidemic.
Interview recorded on May 5th, 2017 in The United Kingdom
People need to WAKE UP! Angela tells her story about her children and her foundation to help others in her area.
Interview recorded on May 5th, 2017 in The United Kingdom
TDap made my husband sick
Vaccinated versus unvaccinated
I now realize the danger of vaccinations
I was a scientist and will now never vaccinate my children
Vaccines gave my son autism
My 3 children are injured from vaccines
I am injured so I will never vaccinate my children
1 Corinthians 15 Authorized (King James) Version (AKJV)
1 Moreover, brethren, I declare unto you the gospel which I preached unto you, which also ye have received, and wherein ye stand;
2 by which also ye are saved, if ye keep in memory what I preached unto you, unless ye have believed in vain.
3 For I delivered unto you first of all that which I also received, how that Christ died for our sins according to the scriptures;
4 and that he was buried, and that he rose again the third day according to the scriptures:
Hebrews 6 Authorized (King James) Version (AKJV)
1 Therefore leaving the principles of the doctrine of Christ, let us go on unto perfection; not laying again the foundation of repentance from dead works, and of faith toward God,
2 of the doctrine of baptisms, and of laying on of hands, and of resurrection of the dead, and of eternal judgment.
3 And this will we do, if God permit.
4 For it is impossible for those who were once enlightened, and have tasted of the heavenly gift, and were made partakers of the Holy Ghost,
5 and have tasted the good word of God, and the powers of the world to come,
6 if they shall fall away, to renew them again unto repentance; seeing they crucify to themselves the Son of God afresh, and put him to an open shame.
7 For the earth which drinketh in the rain that cometh oft upon it, and bringeth forth herbs meet for them by whom it is dressed, receiveth blessing from God:
8 but that which beareth thorns and briers is rejected, and is nigh unto cursing; whose end is to be burned.
Whooping cough resurgence due to vaccinated people not knowing they’re infectious?
Date:
June 24, 2015
Source:
Santa Fe Institute
Summary:
The dramatic resurgence of whooping cough is due, in large part, to vaccinated people who are infectious but who do not display the symptoms, suggests a new study.
…vaccinated people who are infectious but who do not display the symptoms of whooping cough, suggesting that the number of people transmitting without symptoms may be many times greater than those transmitting with symptoms.
The problem is, the newer vaccines might not block transmission. A January 2014 study in PNAS by another research team demonstrated that giving baboons acellular pertussis vaccines prevented them from developing symptoms of whooping cough but failed to stop transmission.
Building on that result, Althouse and Scarpino used whopping cough case counts from the CDC, genomic data on the pertussis bacteria, and a detailed epidemiological model of whooping cough transmission to conclude that acellular vaccines may well have contributed to — even exacerbated — the recent pertussis outbreak by allowing infected individuals without symptoms to unknowingly spread pertussis multiple times in their lifetimes.
Washington, D.C., March 3, 2015 (GLOBE NEWSWIRE) — Physicians and public health officials know that recently vaccinated individuals can spread disease and that contact with the immunocompromised can be especially dangerous. For example, the Johns Hopkins Patient Guide warns the immunocompromised to “Avoid contact with children who are recently vaccinated,” and to “Tell friends and family who are sick, or have recently had a live vaccine (such as chicken pox, measles, rubella, intranasal influenza, polio or smallpox) not to visit.”1
A statement on the website of St. Jude’s Hospital warns parents not to allow people to visit children undergoing cancer treatment if they have received oral polio or smallpox vaccines within four weeks, have received the nasal flu vaccine within one week, or have rashes after receiving the chickenpox vaccine or MMR (measles, mumps, rubella) vaccine.2
“The public health community is blaming unvaccinated children for the outbreak of measles at Disneyland, but the illnesses could just as easily have occurred due to contact with a recently vaccinated individual,” says Sally Fallon Morell, president of the Weston A. Price Foundation. The Foundation promotes a healthy diet, non-toxic lifestyle and freedom of medical choice for parents and their children. “Evidence indicates that recently vaccinated individuals should be quarantined in order to protect the public.”
Scientific evidence demonstrates that individuals vaccinated with live virus vaccines such as MMR (measles, mumps and rubella), rotavirus, chicken pox, shingles and influenza can shed the virus for many weeks or months afterwards and infect the vaccinated and unvaccinated alike.
In 2014, an outbreak of whooping cough (pertussis) broke out in the San Diego area. Of the 621 individuals who were infected, nearly all of them were completely up to date on all preventive vaccinations. If vaccines are given to protect from disease, how could this happen?
San Diego public health official Dr. Wilma Wooten argued that the cause was related to a decrease in the protection offered by vaccines after the first year. This answer is most revealing, in that it speaks to the actual efficacy of vaccines. It also shows that the concept of herd immunity is largely myth—and completely misunderstood.
The theory of herd immunity states that when a critical mass of the population (usually stipulated at 95%) is vaccinated against a disease, the possibility of outbreaks is eliminated. This is the main argument that is used to shame parents who wish to refuse certain vaccinations for their children: by not vaccinating, they put the health of the “herd” at risk.
However, if vaccines start losing effectiveness after the first year, as Dr. Wooten says, then constant revaccination would be required, since the immunity offered is only temporary for most vaccines. Achieving the required rate of protection is virtually impossible under this paradigm.
Of course, if we look back over the decades and note the lack of rampant epidemics in our nation, while remembering that vaccine protection is in perpetual decline, the myth of herd immunity quickly unravels. Our society has never achieved this level of herd immunity, yet not a single major outbreak of disease has occurred.
The argument for herd immunity was actually developed out of observations of natural immunity, not vaccination. Statisticians observed that populations were protected when sufficient members contracted the wild form of a disease, and subsequently acquired lifelong immunity. With vaccines, however, evidence shows that unvaccinated children may catch infectious diseases from vaccinated children. What is true of natural immunity is not true of vaccination.
Adverse Effects of Pertussis and Rubella Vaccines (1991)
Description
Parents have come to depend on vaccines to protect their children from a variety of diseases. Some evidence suggests, however, that vaccination against pertussis (whooping cough) and rubella (German measles) is, in a small number of cases, associated with increased risk of serious illness.
This book examines the controversy over the evidence and offers a comprehensively documented assessment of the risk of illness following immunization with vaccines against pertussis and rubella. Based on extensive review of the evidence from epidemiologic studies, case histories, studies in animals, and other sources of information, the book examines:
The relation of pertussis vaccines to a number of serious adverse events, including encephalopathy and other central nervous system disorders, sudden infant death syndrome, autism, Guillain-Barre syndrome, learning disabilities, and Reye syndrome.
The relation of rubella vaccines to arthritis, various neuropathies, and thrombocytopenic purpura.
The volume, which includes a description of the committee’s methods for evaluating evidence and directions for future research, will be important reading for public health officials, pediatricians, researchers, and concerned parents.
Whooping cough increase related to current vaccine
The move to an artificially created vaccine for whooping cough is behind an increase in cases of the deadly disease in the US, a new study suggests.
The findings highlight the need to do similar research in Australia where whooping cough cases have spiralled upward in the past decade, co-author Associate Professor Manoj Gambhir, from the University of Monash, says.
In 2012 the US saw the highest number of pertussis (whooping cough) cases since 1955.
At the same time there has been a shift in the age group reporting the largest number of cases from adolescents to 7 to 11 year olds.
In the paper, published today in PLOS Computational Biology, Gambhir and colleagues use mathematical modelling of 60 years of pertussis disease data to determine what best explains this increase.
A Change in Vaccine Efficacy and Duration of Protection Explains Recent Rises in Pertussis Incidence in the United States
Published: April 23, 2015 PDF version
Abstract
Over the past ten years the incidence of pertussis in the United States (U.S.) has risen steadily, with 2012 seeing the highest case number since 1955. There has also been a shift over the same time period in the age group reporting the largest number of cases (aside from infants), from adolescents to 7–11 year olds. We use epidemiological modelling and a large case incidence dataset to explain the upsurge. We investigate several hypotheses for the upsurge in pertussis cases by fitting a suite of dynamic epidemiological models to incidence data from the National Notifiable Disease Surveillance System (NNDSS) between 1990–2009, as well as incidence data from a variety of sources from 1950–1989. We find that: the best-fitting model is one in which vaccine efficacy and duration of protection of the acellular pertussis (aP) vaccine is lower than that of the whole-cell (wP) vaccine, (efficacy of the first three doses 80% [95% CI: 78%, 82%] versus 90% [95% CI: 87%, 94%]), increasing the rate at which disease is reported to NNDSS is not sufficient to explain the upsurge and 3) 2010–2012 disease incidence is predicted well. In this study, we use all available U.S. surveillance data to: 1) fit a set of mathematical models and determine which best explains these data and 2) determine the epidemiological and vaccine-related parameter values of this model. We find evidence of a difference in efficacy and duration of protection between the two vaccine types, wP and aP (aP efficacy and duration lower than wP). Future refinement of the model presented here will allow for an exploration of alternative vaccination strategies such as different age-spacings, further booster doses, and cocooning.
FDA NEWS RELEASE – FDA study helps provide an understanding of rising rates of whooping cough and response to vaccination
For Immediate Release: Nov. 27, 2013
A new study is helping to provide a better understanding of vaccines for whooping cough, the common name for the disease pertussis. Based on an animal model, the study conducted by the U.S. Food and Drug Administration (FDA) and published November 25, 2013, in The Proceedings of the National Academy of Sciences, shows that acellular pertussis vaccines licensed by the FDA are effective in preventing the disease among those vaccinated, but suggests that they may not prevent infection from the bacteria that causes whooping cough in those vaccinated or its spread to other people, including those who may not be vaccinated.
While the reasons for the increase in cases of whooping cough are not fully understood, multiple factors are likely involved, including diminished immunity from childhood pertussis vaccines, improved diagnostic testing, and increased reporting. With its own funds plus support from the National Institutes of Health (NIH), the FDA conducted the study to explore the possibility that acellular pertussis vaccines, while protecting against disease, might not prevent infection.
Study- Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model
Although pertussis resurgence is not completely understood, we hypothesize that current acellular pertussis (aP) vaccines fail to prevent colonization and transmission.
To test our hypothesis, infant baboons were vaccinated at 2, 4, and 6 mo of age with aP or whole-cell pertussis (wP) vaccines and challenged with
pertussis at 7 mo. Infection was followed by quantifying colonization in nasopharyngeal washes and monitoring leukocytosis and symptoms. Baboons vaccinated with aP were
protected from severe pertussis-associated symptoms but not from colonization, did not clear the infection faster than naïve animals, and readily transmitted
pertussis to unvaccinated contacts. Vaccination with wP induced a more rapid clearance compared with naïve and aP-vaccinated animals. By comparison, previously infected
animals were not colonized upon secondary infection. Although all vaccinated and previously infected animals had robust serum antibody responses, we found key differences in T-cell immunity.
Previously infected animals and wP-vaccinated animals possess strong pertussis-specific T helper 17 (Th17) memory and Th1 memory,whereas aP vaccination induced a Th1/Th2 response instead. The
observation that aP, which induces an immune response mismatched to that induced by natural infection, fails to prevent colonization or transmission provides a plausible explanation for the
resurgence of pertussis and suggests that optimal control of pertussis will require the development of improved vaccine
the news network 